Eindhoven-based MedTech startup Xyall has secured €7.6 million in funding to expand its automated tissue dissection technology for molecular pathology laboratories globally.
The round was led by Capricorn Partners through its Capricorn Healthtech Fund II, with continued backing from Sioux Technologies, BOM, Health Investment Partners, and private investors.
Founded in 2018 by Guido du Pree and Hans van Wijngaarden, Xyall focuses on digitising and automating one of the most critical and traditionally manual steps in molecular diagnostics: tissue dissection.
Tackling a manual bottleneck in molecular diagnostics
In many pathology labs today, tissue dissection remains a labour-intensive and error-prone process. Pathologists identify Regions of Interest (ROIs) on H&E-stained slides, after which laboratory technicians manually transfer these markings onto dissection slides and physically scrape tissue samples for further molecular testing.
This workflow is not only time-consuming but also difficult to scale. It carries risks of cross-contamination and is increasingly constrained by the global shortage of skilled laboratory technicians.
Xyall’s platform addresses these challenges by integrating high-resolution slide imaging, advanced image registration, workflow optimisation, and precision robotics into a fully automated system. Its solution accurately identifies and dissects ROIs, reduces manual workload, accelerates case processing, and minimizes contamination risk.
Advertisement
From high-throughput systems to compact lab solutions
The company launched its first product, the Tissector High Throughput System, in 2021, targeting large molecular laboratories. The system can hold up to 1,800 slides, process more than 80 slides per hour with accuracy better than 0.1 mm, and operate unattended for up to three hours.
In 2023, Xyall introduced the Tissector Table Top (TT), designed for small to medium-sized labs. The compact system accommodates 72 slides, processes over 30 slides per hour with ≤0.1 mm precision, and runs continuously for more than two hours.
The latest funding will support the global rollout of the Tissector Table Top system, which is already deployed in more than 15 molecular pathology laboratories across the United States, including leading commercial, academic, pharmaceutical, and research institutions.
Bridging morphology and molecular testing
CEO Guido du Pree highlighted the growing gap between rapid advances in PCR and next-generation sequencing technologies and the still-manual process of tumour tissue selection.
He noted that while molecular testing capabilities have evolved significantly, tissue selection remains subjective and imprecise. Xyall’s automated dissection systems aim to bridge this gap, providing a critical link between morphological assessment and molecular diagnostics.
By automating this foundational step, Xyall positions itself at the intersection of robotics, digital pathology, and precision medicine, supporting laboratories in delivering faster, more reliable diagnostic results at scale.
